Par, MN to develop injectables.
SPRING VALLEY, N.Y. -- Par Pharmaceutical Cos. has entered into an alliance with MN Pharmaceuticals for the development of generic injectable pharmaceuticals. Par and Istanbul-based MN will work on as many as 10 products.
"We are pleased to enter into this partnership. MN is one of Turkey's leading and oldest pharmaceutical companies," comments Par president and chief executive officer Scott Tarriff.
MN will be responsible for developing and manufacturing all products covered under the agreement; Par will provide regulatory affairs support and submit abbreviated new drug applications (ANDAs) to the Food and Drug Administration.
Par will also be responsible for litigation expenses that may arise from the ANDA submissions. Par will have exclusive rights to market, sell and distribute products in the United States.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Par Pharmaceutical Inc., MN Pharmaceuticals|
|Publication:||Chain Drug Review|
|Article Type:||Brief Article|
|Date:||Nov 21, 2005|
|Previous Article:||Judge backs Teva exclusivity claim.|
|Next Article:||Wyeth clears the way for generic Effexor.|